Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on March 20, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/4/217    most recent
hyp007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chae, B. J.
Right arrow Articles by Jung, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chae, B. J.
Right arrow Articles by Jung, S. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer

Byung Joo Chae1, Ja Seong Bae1, Ahwon Lee2, Woo Chan Park1, Young Jin Seo1, Byung Joo Song1, Jung Soo Kim1 and Sang Seol Jung1

1 Department of Surgery, Catholic University of Korea
2 Department of Pathology, Catholic University of Korea, Seoul, Republic of Korea

For reprints and all correspondence: Sang Seol Jung, Department of Surgery, Breast Center, KangNam St Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul, Republic of Korea. E-mail: ssjung{at}catholic.ac.kr

Received November 16, 2008; accepted January 11, 2009

Objective: A recent suggestion is that the predictive value of a single biomarker may rely on the genetic background on the tumor and that different breast cancer subgroups may have different predictive markers of response to chemotherapy. The prognostic value of p53 in the outcome of adjuvant anthracycline-containing chemotherapy was evaluated according to molecular subclasses defined using the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2.

Methods: Subjects were patients (n = 135) with invasive ductal carcinoma treated with adjuvant anthracycline-based chemotherapy between 1994 and 2000 in our hospital. Clinico-pathological features were reviewed by retrospective examination of medical records.

Results: Overall survival rate was not independently predictive by p53 status (P = 0.182). However, in triple-negative cases, there was statistically significant survival difference (P = 0.034) and no statistically significant difference (P = 0.783) in non-triple-negative cases by p53 status. In the Cox proportional hazard analysis, p53 was also strongly predictive for relapse-free survival (P = 0.013) and overall survival (P = 0.049) in triple-negative patients.

Conclusions: p53 status could be a specific prognostic factor in triple-negative breast cancer patients treated by adjuvant anthracycline-based regimen. When p53 is positive in triple-negative breast cancer, we could expect poor survival, prompting aggressive or alternative treatment.

Key Words: breast cancer • p53 protein • anthracycline • prognosis • biologic marker


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.